It probably wouldn't be too far-fetched to call Silk Road Medical (Sunnyvale, Calif.) a giant awakening from its slumber. The private company was formed back in 2007, but has remained relatively quiet – amassing funding and securing patents on technology that could be used in transcarotid artery revascularization (TCAR) procedures to reduce the risk of strokes. But the company's quiet phase is rapidly drawing to a close. It just reported it has received up to $57 million in equity and debt funding from new and existing investors.